Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.

Pharmacogenomics - 1 Nov 2017

Kulakova Olga, Bashinskaya Vitalina, Kiselev Ivan, Baulina Natalia, Tsareva Ekaterina, Nikolaev Ruslan, Kozin Maxim, Shchur Sergey, Favorov Alexander, Boyko Alexey, Favorova Olga

Abstract excerpt

AIM: Association analysis of genome-wide association studies (GWAS) identified multiple sclerosis (MS) risk genetic variants with glatiramer acetate (GA) treatment efficacy. PATIENTS & METHODS: SNPs in 17 GWAS-identified immune response loci were analyzed in 296 Russian MS patients as possible markers of optimal GA treatment response for at least 2 years. RESULTS: Alleles/genotypes of EOMES, CLEC16A, IL22RA2,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Genetic Loci

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genome-Wide Association Study

Share to Genotype

Share to Multiple Sclerosis

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 29095108
DOI: 10.2217/pgs-2017-0058

Genes

EOMES
TYK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.PMID 29095108Read ↗

Effects of HLA-DRA, HLA-DQA1 and IL-6 Gene Variations to Glatiramer Acetate Resistance in Multiple Sclerosis Patients.Semantic proximity Read ↗

HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.Semantic proximity Read ↗

GWAS-identified multiple sclerosis risk loci involved in immune response: validation in Russians.Semantic proximity Read ↗

The Multiple Sclerosis (MS) Genetic Risk Factors Indicate both Acquired and Innate Immune Cell Subsets Contribute to MS Pathogenesis and Identify Novel Therapeutic OpportunitiesSemantic proximity Read ↗

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.Semantic proximity Read ↗

Pharmacogenetics of multiple sclerosisSemantic proximity Read ↗

Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.Semantic proximity Read ↗

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.Semantic proximity Read ↗

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.Semantic proximity Read ↗

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.Semantic proximity Read ↗

United Europeans for development of pharmacogenomics in multiple sclerosis network.Semantic proximity Read ↗

Gene expression analysis reveals functional pathways of glatiramer acetate activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.